<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1372">
  <stage>Registered</stage>
  <submitdate>15/11/2006</submitdate>
  <approvaldate>15/11/2006</approvaldate>
  <nctid>NCT00400556</nctid>
  <trial_identification>
    <studytitle>ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells</studytitle>
    <scientifictitle>A Phase I Study of Haematopoietic Stem Cell Mobilization Using G-CSF With ATRA in Patients With Cutaneous Lymphoma and Multiple Myeloma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>04/24</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Myeloma</healthcondition>
    <healthcondition>Cutaneous Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination

Treatment: drugs: ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Toxicity data (NCI-CTC version 2.0 criteria)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>skin toxicity</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>hepatotoxicity</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>mucosal toxicity</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>hematologic toxicity</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>neurologic toxicity</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>treatment response</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CD34+ cell count peak level</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>time to CD34+ count peak level</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>time to reach level &gt;5 x 10^6.L</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>area under curve for duration of time spent with CD34+ count &gt;5 x 10^6/L</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>peripheral blood colony forming unit assays</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>peak CFU-GEMM level</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>time to peak CFU-GEMM level</outcome>
      <timepoint />
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  likely to comply with study protocol

          -  age of 18-70

          -  histologically proven multiple myeloma or lymphoma

          -  not currently receiving cytotoxic agents however thalidomide, prednisolone,
             dexamethasone are allowable

          -  multiple myeloma patients must be receiving regular bisphosphonates

          -  absolute neutrophil count between 1.5 and 10.0 x 10^9/L

          -  ECOG performance status &lt;/= 3

          -  life expectancy of at least two months

          -  written informed consent signed by patient or legally authorised representative</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  use of other vitamin A preparations within the last 30 days

          -  active infection or fever &gt;/= 38.2 degrees celsius

          -  pregnancy or breast feeding. Women of child bearing potential admitted to the trial
             must take adequate measures to prevent conception (at least two different forms of
             contraception) and are to undergo a pregnancy test. Oral contraception must not
             include low-dose progestogens

          -  known allergy to E.coli derived products

          -  current treatment with tetracycline antibiotics</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Peter MacCallum Cancer Center - East Melbourne</hospital>
    <postcode>3002 - East Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Peter MacCallum Cancer Centre, Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The Leukemia and Lymphoma Society</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Hematopoietic stem and progenitor cells (HSPC) are used for transplantation in patients
      undergoing high dose therapy for the treatment of a range of cancers.

        -  HSPC are collected from the bloodstream after treatment with medications that cause the
           HSPC to move from the bone marrow into the bloodstream, a process called mobilization

        -  between 5 and 60% of patients can fail to collect enough HSPC for a transplant, using
           current mobilization techniques

        -  this study aims to assess the safety of combining a derivative of vitamin A, ATRA with
           G-CSF (the drug most commonly used to mobilize HSPC)

        -  ATRA has never been combined with G-CSF for mobilization of HSPC and therefore a study
           is needed to assess the safety of this combination, and whether it successfully
           mobilizes HSPC</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00400556</trialwebsite>
    <publication>Herbert KE, Walkley CR, Winkler IG, Hendy J, Olsen GH, Yuan YD, Chandraratna RA, Prince HM, LÃ©vesque JP, Purton LE. Granulocyte colony-stimulating factor and an RARalpha specific agonist, VTP195183, synergize to enhance the mobilization of hematopoietic progenitor cells. Transplantation. 2007 Feb 27;83(4):375-84.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kirsten E Herbert, MBBS</name>
      <address>Peter MacCallum Cancer Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>